The trial -- 'India-UK RECOVERY (Randomised Evaluation of COVID-19 therapy)' -- will be a multi-centre, adaptive platform trial on Covid patients, ICMR said on Friday.
The goal of the trial is to evaluate the safety, tolerability and immunogenicity of the HIVconsvX vaccine -- a mosaic vaccine targeting a broad range of HIV-1 variants, making it potentially applicable for HIV strains in any geographical region.
This study, published on the Lancet pre-print server, means all possible vaccination schedules involving the Oxford-AstraZeneca and Pfizer-BioNTech vaccines could potentially be used against COVID-19.
Delhi's All India Institute of Medical Sciences (AIIMS) has moved past prestigious institutes in the rankings for best medical schools in the world. According to tthe CEOWORLD magazine, AIIMS stood 23rd in the list, securing of 86.38.
Previous studies of ivermectin, which show that early administration with ivermectin can reduce viral load and the duration of symptoms in some patients with mild Covid, have generally been small or low quality.
A low number of platelets- blood cells that help prevent blood loss when vessels are damaged-can result in no symptoms or can lead to an increased risk of bleeding or, in some cases, clotting.
Both Serum Institute of India (SII) and Bharat Biotech would be ramping up production of Covid vaccines in India from July. SII is manufacturing Oxford-AstraZeneca vaccine called Covishield in India, while Bharat Biotech is producing Covaxin.
Those given a first dose of either of the two vaccines currently being administered by the National Health Service (NHS) and who became infected with SARS-Cov-2 – the coronavirus which causes COVID-19 – three weeks later were between 38 and 49 per cent less likely to pass the virus on than unvaccinated people.
The UK’s medicines regulator on Wednesday said that under-30s in the country will be offered an alternative to the Oxford/AstraZeneca vaccine due to "evolving evidence” linking it to rare blood clots, even as the European Medicines Agency (EMA) concluded a "possible link" between the vaccine and rare clotting.
The Oxford–AstraZeneca Covid-19 vaccine, a version of which is also being used in India, is made from an adenovirus isolated from chimpanzee poop, which has been genetically changed so that it is impossible for it to grow in humans.
Chen added that in the UK, a high proportion of patients have long Covid-19, but reasons for this phenomenon is not clear so far.
The government on Monday revised the interval between two doses of Oxford-AstraZeneca's Covishield vaccine.
The COVID-19 vaccine developed by Oxford University and bio-pharmaceutical major AstraZeneca is safe and works extremely well, UK Prime Minister Boris Johnson said on Tuesday, amid reports that the doses were causing blood clot-related complications.
Data suggests that in the over 80s, a single dose of either vaccine is more than 80 per cent effective at preventing hospitalisation, around 3 to 4 weeks after the jab, PHE said in a statement.
Just one vaccine shot reduces the risk of being hospitalised by Covid-19 by more than 90 per cent, according to new findings, Daily Mail reported.
A three-month interval between doses of the Oxford COVID-19 vaccine results in higher vaccine efficacy than a six-week gap, according to a new study which says the first dose can offer up to 76 per cent protection in the months between the two jabs.
Speaking at the daily press briefing, Dr. Tedros Adhanom Ghebreyesus, WHO Director-General, said, "Today, WHO gave emergency use listing to two versions of the Oxford-AstraZeneca vaccine, giving the green light for these vaccines to be rolled out globally through COVAX."
The University of Oxford has launched the first study to assess the safety and immune responses in children and young adults of its coronavirus vaccine.
The COVID-19 vaccine developed by Oxford University and produced by AstraZeneca has shown efficacy against the UK variant of the coronavirus, according to an ongoing study by researchers.
Top News
Latest News
